Longitude Cayman Ltd. Sells 750,000 Shares of Amarin Co. plc (NASDAQ:AMRN)

Longitude Cayman Ltd. cut its holdings in shares of Amarin Co. plc (NASDAQ:AMRN) by 31.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,620,000 shares of the biopharmaceutical company’s stock after selling 750,000 shares during the period. Longitude Cayman Ltd. owned approximately 0.39% of Amarin worth $786,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Arkfeld Wealth Strategies L.L.C. boosted its holdings in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 20,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Amarin by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 29,992 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in Amarin by 80.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 42,700 shares during the last quarter. LCM Capital Management Inc boosted its holdings in Amarin by 3.1% during the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 25,100 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Amarin by 8.8% during the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 104,939 shares during the last quarter. 22.25% of the stock is owned by institutional investors.

Amarin Stock Down 3.3 %

AMRN opened at $0.52 on Tuesday. The stock has a market cap of $214.94 million, a price-to-earnings ratio of -5.82 and a beta of 1.83. Amarin Co. plc has a twelve month low of $0.43 and a twelve month high of $1.36. The company’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $0.57.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Amarin from a “hold” rating to a “sell” rating in a report on Friday, January 24th.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.